EGFR-mutant lung adenocarcinomas mutation profiles reveal ARID1A might be a novel tyrosine kinase resistance pathway

被引：0

作者：

Gao, Xuyuan ^{[1
]}

Xu, Hang ^{[2
]}

Ho, James C. M. ^{[3
]}

Chan, Oscar S. H. ^{[4
]}

Xu, Feng ^{[5
]}

Wang, Junwen ^{[6
]}

Lee, Victor H. F. ^{[7
]}

Tin, Vicky P. C. ^{[1
]}

Xiao, Zhijie ^{[1
]}

Wang, Siqi ^{[1
]}

Yam, Judy W. P. ^{[1
]}

Wong, Maria P. ^{[1
]}

机构：

[1] Univ Hong Kong, Dept Pathol, Hong Kong, Peoples R China

[2] Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China

[3] Univ Hong Kong, Dept Med, Hong Kong, Peoples R China

[4] Pamela Youde Nethersole Eastern Hosp, Dept Clin Oncol, Hong Kong, Peoples R China

[5] Univ British Columbia, St Pauls Hosp, Providence Hlth Care, Vancouver, BC, Canada

[6] Mayo Clin, Scottsdale, AZ USA

[7] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-LB-196

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LB-196

引用

页数：2

共 50 条

[21] Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer
Zhu, Viola W.
Klempner, Samuel J.
Ou, Sai-Hong Ignatius
TRENDS IN CANCER, 2019, 5 (11): : 677 - 692
[22] Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
Santoni-Rugiu, Eric
Melchior, Linea C.
Urbanska, Edyta M.
Jakobsen, Jan N.
de Stricker, Karin
Grauslund, Morten
Sorensen, Jens B.
CANCERS, 2019, 11 (07)
[23] Disease flare after tyrosine kinase inhibitor (TKI) discontinuation in patients with EGFR-mutant lung cancer and acquired resistance
Chaft, J. E.
Oxnard, G. R.
Miller, V. A.
Kris, M. G.
Sima, C. S.
Riely, G. J.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[24] Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer
de Miguel, Fernando J.
Gentile, Claudia
Feng, William W.
Silva, Shannon J.
Sankar, Akshay
Exposito, Francisco
Feng, Wesley L.
Melnick, Mary Ann
Robles-Oteiza, Camila
Hinkley, Madeline M.
Tsai, Jeanelle A.
Hartley, Antja-Voy
Wei, Jin
Wurtz, Anna
Li, Fangyong
Toki, Maria I.
Rimm, David L.
Homer, Robert
Wilen, Craig B.
Xiao, Andrew Z.
Qi, Jun
Yan, Qin
Nguyen, Don X.
Janne, Pasi A.
Kadoch, Cigall
Politi, Katerina A.
CANCER CELL, 2023, 41 (08) : 1516 - +
[25] Acquired resistance to epidermal growth factor receptor (EGFR) kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma
Bean, J.
Riely, G. J.
Balak, M.
Marks, J. L.
Ladanyi, M.
Miller, V. A.
Pao, W.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[26] Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas
Eng, Juliana
Woo, Kaitlin M.
Sima, Camelia S.
Plodkowski, Andrew
Hellmann, Matthew D.
Chaft, Jamie E.
Kris, Mark G.
Arcila, Maria E.
Ladanyi, Marc
Drilon, Alexander
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (12) : 1713 - 1719
[27] Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
Zhang, Zhe
Yang, Sen
Wang, Qiming
BIOMARKER RESEARCH, 2019, 7 (01)
[28] Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
Zhe Zhang
Sen Yang
Qiming Wang
Biomarker Research, 7
[29] Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation
Becker, Kevin
Xu, Yiqing
WORLD JOURNAL OF CLINICAL ONCOLOGY, 2014, 5 (04): : 560 - 567
[30] Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition
Soucheray, Margaret
Capelletti, Marzia
Pulido, Ines
Kuang, Yanan
Paweletz, Cloud P.
Becker, Jeffrey H.
Kikuchi, Eiki
Xu, Chunxiao
Patel, Tarun B.
Al-Shahrour, Fatima
Carretero, Julian
Wong, Kwok-Kin
Jaenne, Pasi A.
Shapiro, Geoffrey I.
Shimamura, Takeshi
CANCER RESEARCH, 2015, 75 (20) : 4372 - 4383

← 1 2 3 4 5 →